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Diversity and complexity of mouse allergens in allergenic products assessed with an immunoallergomic approach Samuel T. Mindaye, PhD, Sayyed Amin Zarkesh Esfahani, Ronald L. Rabin, MD FAAAAI, and Jay E. Slater, MD; FDA/CBER/OVRR/DBPAP, Silver Spring, MD. RATIONALE: Mouse allergy is common among laboratory animal workers and infested homes. The predominant allergen, Mus m 1, is part of the Mouse Urinary Proteins (MUPs) complex. The full diversity and immunogenic potential of MUPs have not been fully established yet, and it is not clear that MUPs are the only relevant sensitizing agents. This work investigates the diversity and relative immunogenicity of various MUPs. METHODS: Liquid chromatography/mass spectrometry (LC/MS) was used for deep proteomic analysis of mouse urine and epithelial extracts. Mouse proteins, resolved by two-dimensional polyacrylamide gel electrophoresis, were screened against IgG and IgE. Reactive spots were picked and examined using LC/MS. Finally, a multiple reaction monitoring (MRM) method was developed for total MUP as well as isoform-specific quantification. LC/MS and MRM results were compared to Mus m 1 quantification by ELISA. RESULTS: We established a global proteomic signature and a detailed profile of MUPs including their post-translationally modified variants in commercial products and in collected mouse urine. MUP3 resolved into four different protein forms while MUP19 appears to have three protein variants. Using bioinformatics and sequence analyses, we identified unique tryptic peptides for 10 MUPs. Isotopically-labeled unique reference peptides were chemically synthesized and used to develop an MRM method for isoform-specific quantification of MUPs. The MRM assay is being evaluated for comparability with various ELISA assays of Mus m 1. CONCLUSIONS: We established molecular and immunogenic fingerprints of mouse epithelial and urinary allergenic products. The results are key in guiding research, characterization, quality control, and standardization of existing and future products. Ottawa Allergy Research Corporation, Ottawa, ON, Canada. RATIONALE: Cat dander is a common cause of allergic rhinitis. A cat exposure room with allergen concentrations similar to homes with cats can provide a relevant model to test allergy medications. We assessed the reproducibility of the clinical response in cat allergic and non-allergic subjects, in a natural exposure chamber (NEC). METHODS: Six subjects (4 allergic and 2 non-allergic) underwent 2 challenges, one week apart. During the challenges cat bedding was shaken every 15 minutes; nasal, ocular and respiratory symptoms were captured every 5 minutes using a 4-point severity scale and spirometry was performed every 15 minutes outside the NEC. Aerosolized Fel d1 sampled by portable pumps (Gilian 5000) was measured at 3 room locations and from a sampler worn by the subject. Fel d1 was also measured from swabs obtained from walls and the floor. RESULTS: Room Fel d 1 was 189.56183.4 ng/m 3 ; personal samplers reported 63.4651.2 ng/m 3 . Rhinoconjunctivitis symptoms for the two challenges in the 4 cat-allergic subjects were similar (6.561.7 vs. 6.2563.36). Nasal symptoms predominated (5.2562.1, Challenge 1; 4.062.4, Challenge 2). Allergic subjects reported modest respiratory discomfort during the challenges although none experienced a fall in FEV 1 . The 2 non-cat allergic subjects experienced no nasal, ocular or respiratory symptoms. CONCLUSIONS: The NEC maintains airborne Fel d1 levels similar to homes and induces symptoms in allergic subjects while non-allergic subjects remain asymptomatic. Rhinoconjunctivitis and respiratory symptoms were comparable in two sessions separated by a week indicating that the NEC would be suitable for evaluating the effects of treatment.
